KRAS and malignant colon neoplasm: This is significant considering growing interest in NEK9 as a therapeutic target in p53‐mutant cancers including KRAS‐mutant colon cancer and non‐small‐cell lung cancer (NSCLC) (Kurioka et al., 2014).